Naar www.iknl.nl
- Palliatieve Zorg > Ascites
Notificatie richtlijn E-mail richtlijn Naar startpagina oncoline
----------

Versie: 2.0, Redactionele aanpassing 2018-01-01 , Verantwoording: Palliatieve zorg: richtlijnen voor de praktijk, Type: Landelijke richtlijn

Referentielijst

1 - Adam RA (2004)
Adam RA, Adam YG. Malignant ascites: past, present and future. Journal of the American College of Surgeons 2004; 198: 999-1011.
 
2 - Appelqvist P (1982)
Appelqvist P, Silvo J, Salmela L et al. On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed? Journal of Surgical Oncology 1982; 20: 238-242.
 
3 - Ariel IM (1966)

Ariel IM, Oropeza R, Pack GT. Intracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patients. Cancer 1966; 19: 1096-1102.

 
4 - Aslam N (2001)
Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis and management. Archives of Internal Medicine 2001; 161: 2733-2737.
 
5 - Ayantunde AA (2007)
Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Annals of Oncology 2007; 18: 945-949.
 
6 - Becker G (2006)
Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. European Journal of Cancer 2006; 42: 589-597.
 
7 - Bieligk SC (2001)
Bieligk SC, Calvo BF, Coit DG. Peritoneovenous shunting for nongynecologic malignant ascites. Cancer 2001; 91: 1247-1255.
 
8 - Card RY (1960)

Card RY, Cole DR, Henschke UK. Summary of ten years of the use of radioactive colloids in intracavitary therapy. Journal of Nuclear Medicine 1960; 1: 195-198.

 
9 - Chung M (2008)
Chung M, Kozuch P. Treatment of malignant ascites. Current Treatment Options In Oncology 2008; 9: 215-233.
 
10 - Courtney A (2008)
Courtney A, Nemcek AA, Rosenberg S et al. Prospective evaluation of the PleurX catheter when used to treat recurrent ascites associated with malignancy. Journal of Vascular and Interventional Radiology 2008; 19: 1723-1731.
 
11 - Easson AM (2007)
Easson AM, Bezjak A, Ross S et al. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Annals of Surgical Oncology 2007; 14: 2348-2357.
 
12 - Fleming ND (2009)
Fleming ND, Alvarex-Secord A, Gruenigen van V et al. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. Journal of Pain and Symptom Management 2009; 38: 341-349.
 
13 - Gotlieb WH (1998)
Gotlieb WH, Feldman B, Feldman-Moran O et al. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynecologic Oncology 1998; 71: 381-385.
 
14 - Gough IR (1993)
Gough IR, Balderson GA. Malignant ascites. A comparison of peritoneovenous shunting and nonoperative management. Cancer 1993; 71: 2377-2382.
 
15 - Greenway B (1982)
Greenway B, Johnson PJ, Williams R. Control of malignant ascites with spironolactone. British Journal of Surgery 1982; 69: 441-442.
 
16 - Halpin TF (1971)
Halpin TF, McCann TO. Dynamics of body fluids following the rapid removal of large volumes of ascites. American Journal of Obstetrics and Gynecology 1971; 110: 103-106.
 
17 - Jackson ML (1981)

Jackson GL, Blosser NM. Intracavitary chromic phosphate (32P) colloidal suspension therapy. Cancer 1981; 48: 2596-2598.

 
18 - Jacobs ML (1958)

Jacobs ML. Radioactive colloidal chromic phosphate to control pleural effusion and ascites. Journal of the American Medical Association 1958; 166: 597-599.

 
19 - Lee CW (1998)
Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. Journal of Pain and Symptom Management 1998; 16: 96-101.
 
20 - Lee A (2000)
Lee A, Lau TN, Yeong KY. Indwelling catheters for the management of malignant ascites. Supportive Care in Cancer 2000; 8: 493-499.
 
21 - MacDonald R (2006)
MacDonald R, Kirwan J, Roberts S et al. Ovarian cancer and ascites: a questionnaire on current management in the United Kingdom. Journal of Palliative Medicine 2006; 9: 1264-1270.
 
22 - Mackey JR (1996)
Mackey JR, Venner PM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Canadian Journal of Oncology 1996; 6: 474-480.
 
23 - McNamara P (2000)
McNamara P. Paracentesis – an effective method of symptom control in the palliative care setting? Palliative Medicine 2000; 14: 62-64.
 
24 - Mercadante S (2008)
Mercadante S, Intravaia G, Ferrera P et al. Peritoneal catheter for continuous drainage of ascites in advanced cancer patients. Supportive Care In Cancer 2008; 16: 975-978.
 
25 - Monsky WL (2009)
Monsky WL, Yoneda KY, MacMillan J et al. Peritoneal and pleural ports for management of refractory ascites and pleural effusions: assessment of impact on patient quality of life and hospice/home nursing care. Journal of Palliative Medicine 2009; 12: 811-817.
 
26 - Moorsom D (2001)
Moorsom D. Paracentesis in a home care setting. Palliative Medicine 2001; 15: 169-170.
 
27 - Parsons SL (1996)
Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2-year review from a teaching hospital. European Journal of Surgical Oncology 1996; 22: 237-239.
 
28 - Pockros PJ (1992)
Pockros PJ, Esrason KT, Nguyen C et al. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 1992; 103: 1302-1306.
 
29 - Razis DV (1976)
Razis DV, Athanasiou A, Dadiotis L et al. Diuretics in malignant effusions and edemas of generalized cancer. Journal of Medicine 1976; 7: 449-461.
 
30 - Rosenberg S (2004)
Rosenberg S, Courtney A, Nemeck AA Jr et al. Comparison of percutaneous management techniques for recurrent malignant ascites. Journal of Vascular and Interventional Radiology 2004; 15: 1129-1131.
 
31 - Runyon BA (1986)
Runyon BA. Paracentesis of ascitic fluid. A safe procedure. Archives of Internal Medicine 1986; 146: 2259-2261.
 
32 - Runyon BA (1988)
Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988; 8: 1104-1109.
 
33 - Runyon BA (1992)
Runyon BA, Montano AA, Akrivadis EA et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Annals of Internal Medicine 1992; 117: 215-220.
 
34 - Sadeghi B (2000)
Sadeghi B, Arvieux C, Glehen O et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358-363.
 
35 - Seike M (2007)
Seike M, Maetani I, Sakai Y. Treatment of malignant ascites In patients with advanced cancer: peritoneovenous shunt versus paracentesis. Journal of Gastroenterology and Hepatology 2007; 22: 2161-2166
 
36 - Sharma S (1995)
Sharma S, Walsh D. Management of symptomatic malignant ascites with diuretics: two case reports and a review of the literature. Journal of Pain and Symptom Management 1995; 10: 237-242.
 
37 - Stephenson J (2002)
Stephenson J, Gilbert J. The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliative Medicine 2002; 16: 213-218.
 
38 - Williams JW (1992)
Williams JW Jr, Simel DL. The rational clinical examination. Does this patient have ascites? How to divine fluid in the abdomen. JAMA 1992; 267: 2645-2648.
 
39 - Zanon C (2002)
Zanon C, Grosso M, Aprà F et al. Palliative treatment of malignant refractory ascites by positioning of Denver peritoneovenous shunt. Tumori 2002; 88: 123-127.